Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–4 of 4 results
Advanced filters: Author: Vesal Yaghoobi Clear advanced filters

  • Targeting Siglec-15 may be an effective alternative therapy for patients that do not respond to PD-1/PD-L1 inhibition. In this study, the authors show broad expression of this potential immune modulatory target in a wide range of cancer types. These data may inform future clinical development and show potential for future companion diagnostic tests for Siglec-15 therapeutics.

    • Saba Shafi
    • Thazin Nwe Aung
    • David L. Rimm
    Research
    Laboratory Investigation
    Volume: 102, P: 1143-1149

  • Siglec-15 is normally expressed by myeloid cells and upregulated in some human cancers and represents a promising new target for immunotherapy. The aim of this study was to develop an immunohistochemical assay for Siglec-15 to be used as a companion diagnostic for future clinical trials. Here, the authors created and validated an assay with a novel recombinant antibody to the cytoplasmic domain of Siglec-15. This study may support development of a companion diagnostic assay to enrich for patients expressing the Siglec-15 target for therapy.

    • Saba Shafi
    • Thazin Nwe Aung
    • David L. Rimm
    Research
    Laboratory Investigation
    Volume: 102, P: 771-778

  • The antibody drug conjugate (ADC) Trastuzumab deruxtecan (T-DXd) has shown activity in breast cancer with low levels of HER2 expression. The historical/conventional assays for HER2 were designed separate high levels of HER2 from intermediate levels and show no expression in the low range. In this study, we determine the optimal dynamic range for unamplified HER2 detection in breast cancer and then design a quantitative assay to stratify HER2 expression in unamplified cases. Assessment of HER2 protein in the optimal dynamic range will ultimately help select the optimal patients for T-DXd and this work can serve as a model for other assays for ADCs where pathology reads may be less accurate that protein measurements.

    • Myrto Moutafi
    • Charles J. Robbins
    • David L. Rimm
    Research
    Laboratory Investigation
    Volume: 102, P: 1101-1108